These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 21133749)

  • 1. Pharmacists correcting schedule II prescriptions: DEA flip-flops continue.
    Abood RR
    J Pain Palliat Care Pharmacother; 2010 Dec; 24(4):393-6. PubMed ID: 21133749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DEA grants prescriber numbers to certain Massachusetts pharmacists.
    J Pain Palliat Care Pharmacother; 2011; 25(3):297-9. PubMed ID: 21998842
    [No Abstract]   [Full Text] [Related]  

  • 3. New Drug Enforcement Administration guideline for communicating controlled substance prescriptions to pharmacies.
    Drug Enforcement Adminstration U S Department of Justice
    J Pain Palliat Care Pharmacother; 2011; 25(1):83-9. PubMed ID: 21426229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution.
    Mott DA; Cline RR
    Med Care; 2002 Aug; 40(8):662-74. PubMed ID: 12187180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the DEA's new "prescription series" regulation balanced?
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2008; 22(3):218-20. PubMed ID: 19042852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The federal Drug Enforcement Administration "prescription series" proposal: continuing concerns.
    Gilson AM; Joranson DE
    J Pain Palliat Care Pharmacother; 2007; 21(4):21-4. PubMed ID: 18032312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Issuance of multiple prescriptions for schedule II controlled substances. Final rule.
    Drug Enforcement Administration (DEA), Department of Justice
    Fed Regist; 2007 Nov; 72(222):64921-30. PubMed ID: 18038486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prescriptions; requirements clarification--Drug Enforcement Administration (DEA). Final rule.
    Fed Regist; 1991 Jun; 56(106):25025-7. PubMed ID: 10111144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DEA issues new clarification regarding prescribing schedule II controlled substances.
    Heitz R
    WMJ; 2005 Apr; 104(3):55. PubMed ID: 15966635
    [No Abstract]   [Full Text] [Related]  

  • 10. Doctors with multi-state practices beware: new DEA regulation could affect you.
    Ball FR
    J Med Pract Manage; 2007; 23(2):104-5. PubMed ID: 17974088
    [No Abstract]   [Full Text] [Related]  

  • 11. DEA issues proposed rule on e-prescribing.
    Ball FR
    J Med Pract Manage; 2009; 24(4):243. PubMed ID: 19288650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The DEA's Balancing Act to Ensure Public Health and Safety.
    Rannazzisi JT
    Clin Pharmacol Ther; 2007 Jun; 81(6):805-6. PubMed ID: 17505495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Drug Enforcement Agency and DEA Form 104.
    Stratton WT
    Kans Med; 1994 Oct; 95(10):212, 214. PubMed ID: 7815771
    [No Abstract]   [Full Text] [Related]  

  • 14. Registration and reregistration application fees. Final rule; remanded for further notice and comment.
    Drug Enforcement Administration (DEA), Justice
    Fed Regist; 1996 Dec; 61(251):68624-6. PubMed ID: 12192680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescriber-pharmacist collaboration: re-engineering the partnership to optimize pain patient care.
    Ruble JH
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):365-6. PubMed ID: 24143929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The International Academy of Compounding Pharmacists stepping up efforts to remedy problems caused by the U.S. Drug Enforcement Administration's "constructive transfer" policy.
    Miller DG
    Int J Pharm Compd; 2012; 16(2):94-6. PubMed ID: 23050319
    [No Abstract]   [Full Text] [Related]  

  • 17. On-the-ground application of the 'temporary recommendation for use' regulatory measure on off-label use of baclofen for alcohol dependence in France: a regional survey of community pharmacies.
    Auffret M; Rolland B; Caous AS; Gaboriau L; Deheul S; Bordet R; Gautier S
    Fundam Clin Pharmacol; 2018 Apr; 32(2):234-238. PubMed ID: 29143356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating community pharmacists' perceptions of future generic substitution policy implementation: a national survey from Malaysia.
    Chong CP; Hassali MA; Bahari MB; Shafie AA
    Health Policy; 2010 Jan; 94(1):68-75. PubMed ID: 19762106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing access to emergency contraceptive pills through state law enabled dependent pharmacist prescribers.
    Field HM
    UCLA Womens Law J; 2000; 11(1):141-253. PubMed ID: 16273688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug enforcement administration liability for false arrest of physician.
    Brushwood DB
    J Pain Palliat Care Pharmacother; 2009; 23(2):156-62. PubMed ID: 19492217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.